Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | ctDNA: bladder cancer management & assessment

Alexander Wyatt • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer

Alexander Wyatt, PhD, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada, discusses the use of circulating tumor DNA (ctDNA) in the management and risk assessment of muscle invasive bladder cancer. Specifically, Dr Wyatt gives and overview of how ctDNA analysis can allow for the characterization of disease biology on an extremely deep level and lead to molecularly driven trials. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Alexander Wyatt

Redefining patient selection for immunotherapy in MIBC
1:18
Redefining patient selection for immunotherapy in MIBC
Alexander Wyatt • 19 Oct 2025
Germline CDK12 variants as a rare predisposition factor in prostate cancer
2:16
Germline CDK12 variants as a rare predisposition factor in prostate cancer
Alexander Wyatt • 19 Oct 2025
Implementing ctDNA-based MRD testing in bladder cancer
1:28
Implementing ctDNA-based MRD testing in bladder cancer
Alexander Wyatt • 19 Oct 2025
IMvigor011: ctDNA-guided adjuvant atezolizumab in MIBC
2:31
IMvigor011: ctDNA-guided adjuvant atezolizumab in MIBC
Alexander Wyatt • 19 Oct 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals